Which is better, MTD or PCRX?

On the Buffett-Fit framework, Mettler-Toledo International Inc. (MTD) currently grades higher than PCRX — 69/100 (B grade) vs 45/100 (D). That said, "better" depends on which framework you trust — MTD wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; PCRX wins on none. The full pillar breakdown is on this page.

Should I buy MTD or PCRX?

This page is an educational comparison, not investment advice. Both MTD and PCRX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is MTD better than PCRX for value investing?

On the Buffett-style value-investing framework, MTD currently grades higher — 69/100 vs 45/100, a 24-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between MTD and PCRX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). MTD currently scores 69/100 (B grade); PCRX scores 45/100 (D grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, MTD or PCRX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. MTD and PCRX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, MTD or PCRX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are MTD and PCRX both Healthcare stocks?

Yes — both Mettler-Toledo International Inc. (MTD) and Pacira BioSciences, Inc. (PCRX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this MTD vs PCRX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Mettler-Toledo International

Pacira BioSciences

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

MTD

Market cap

$22.29B

Sector

Healthcare

PCRX

Pacira BioSciences

Market cap

$918.47M

Sector

Healthcare

Overall winner

Mettler-Toledo International MTD

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	MTD	PCRX	Winner
Warren Buffett	69B	45D	MTD
Benjamin Graham	65B	55D	MTD
Philip Fisher	63C	41D	MTD
Peter Lynch	66B	16F	MTD
Joel Greenblatt	68B	43D	MTD
Charlie Munger	74B	41D	MTD
Terry Smith	70B	41D	MTD

Side-by-side metrics

Metric	MTD	PCRX
Market cap	$22.29B	$918.47M
P/E (TTM)	25.3x	181.4x
EV/EBIT	21.6x	35.2x
ROIC (TTM)	36.09%	0.8%
Gross margin	57.79%	79.34%
Net margin	21.4%	0.7%
Revenue CAGR 5y	2.01%	7.62%
EPS CAGR 5y	6.12%	-35.94%
Debt / Equity	-	0.6x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

MTD leads on

EPS CAGR 5y6.12%vs -35.94%+117%
Debt / Equity-vs 0.6x+101%
ROIC (TTM)36.09%vs 0.8%+98%
Net margin21.4%vs 0.7%+97%

PCRX leads on

Revenue CAGR 5y7.62%vs 2.01%+74%
Gross margin79.34%vs 57.79%+27%

More like MTD

MTD vs IDXX MTD vs 7741.T MTD vs GMAB MTD vs LMAT MTD vs HALO MTD vs SUNPHARMA.NS

More like PCRX

PCRX vs IDXX PCRX vs 7741.T PCRX vs GMAB PCRX vs LMAT PCRX vs HALO PCRX vs SUNPHARMA.NS

Read the full Buffett-Brain analysis for MTD Read the full Buffett-Brain analysis for PCRX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Mettler-Toledo International

Pacira BioSciences

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

MTD

Mettler-Toledo International

Market cap

$22.29B

Sector

Healthcare

PCRX

Pacira BioSciences

Market cap

$918.47M

Sector

Healthcare

Overall winner

Mettler-Toledo International MTD

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	MTD	PCRX	Winner
Warren Buffett	69B	45D	MTD
Benjamin Graham	65B	55D	MTD
Philip Fisher	63C	41D	MTD
Peter Lynch	66B	16F	MTD
Joel Greenblatt	68B	43D	MTD
Charlie Munger	74B	41D	MTD
Terry Smith	70B	41D	MTD

Side-by-side metrics

Metric	MTD	PCRX
Market cap	$22.29B	$918.47M
P/E (TTM)	25.3x	181.4x
EV/EBIT	21.6x	35.2x
ROIC (TTM)	36.09%	0.8%
Gross margin	57.79%	79.34%
Net margin	21.4%	0.7%
Revenue CAGR 5y	2.01%	7.62%
EPS CAGR 5y	6.12%	-35.94%
Debt / Equity	-	0.6x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

MTD leads on

EPS CAGR 5y6.12%vs -35.94%+117%
Debt / Equity-vs 0.6x+101%
ROIC (TTM)36.09%vs 0.8%+98%
Net margin21.4%vs 0.7%+97%

PCRX leads on

Revenue CAGR 5y7.62%vs 2.01%+74%
Gross margin79.34%vs 57.79%+27%

More like MTD

MTD vs IDXX MTD vs 7741.T MTD vs GMAB MTD vs LMAT MTD vs HALO MTD vs SUNPHARMA.NS

More like PCRX

PCRX vs IDXX PCRX vs 7741.T PCRX vs GMAB PCRX vs LMAT PCRX vs HALO PCRX vs SUNPHARMA.NS

Read the full Buffett-Brain analysis for MTD Read the full Buffett-Brain analysis for PCRX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.